Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).
Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, Gaye E, Guimbaud R, Baconnier M, Hautefeuille V, Do Cao C, Petorin C, Hentic O, Perrier M, Aparicio T, Scoazec JY, Bonjour M, Gibert B, Hervieu V, Poncet D, Barritault M, Gerard L, Durand A; “Groupe d’étude des tumeurs endocrines (GTE)” and the French ENDOCAN-RENATEN network. Walter T, et al. Among authors: durand a. J Clin Oncol. 2024 Nov 25:JCO2302724. doi: 10.1200/JCO.23.02724. Online ahead of print. J Clin Oncol. 2024. PMID: 39586038
Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma.
Couronne T, Girot P, Hadoux J, Lecomte T, Durand A, Fine C, Vandevoorde K, Lombard-Bohas C, Walter T. Couronne T, et al. Among authors: durand a. Endocr Connect. 2020 Jun;9(6):498-505. doi: 10.1530/EC-20-0192. Endocr Connect. 2020. PMID: 32380470 Free PMC article.
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, Tauveron I, Laboureau S, Do Cao C, Walter T, Petorin C, Blanchet O, Jannin A, Gu C, Faron M, Leteurtre E, Rousselet MC, Zakeyh JJ, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Ducreux M, Scoazec JY, Baudin E. Hadoux J, et al. Among authors: durand a. Eur J Cancer. 2021 Jul;152:100-115. doi: 10.1016/j.ejca.2021.04.030. Epub 2021 Jun 3. Eur J Cancer. 2021. PMID: 34090142
Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.
Fosse A, Hadoux J, Girot P, Beron A, Afchain P, Cottereau AS, Baudin E, Dierickx LO, Lecomte T, Perrier M, Lepage C, Bouhier-Leporrier K, Goichot B, Lachachi B, Walter T, Durand A. Fosse A, et al. Among authors: durand a. J Nucl Med. 2024 Sep 3;65(9):1416-1422. doi: 10.2967/jnumed.123.267363. J Nucl Med. 2024. PMID: 39089810
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms.
Gerard L, Patte C, Chardon L, Hervieu V, Payen L, Allio M, Marx C, Clermidy H, Durand A, Mehlen P, Bollard J, Poncet G, Roche C, Gibert B, Walter T. Gerard L, et al. Among authors: durand a. Endocr Relat Cancer. 2024 May 10;31(6):e240052. doi: 10.1530/ERC-24-0052. Print 2024 Jun 1. Endocr Relat Cancer. 2024. PMID: 38642579
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
Frizziero M, Durand A, Taboada RG, Zaninotto E, Luchini C, Chakrabarty B, Hervieu V, Claro LCL, Zhou C, Cingarlini S, Milella M, Walter T, Riechelmann RS, Lamarca A, Hubner RA, Mansoor W, Valle JW, McNamara MG. Frizziero M, et al. Among authors: durand a. Cancers (Basel). 2021 Aug 18;13(16):4152. doi: 10.3390/cancers13164152. Cancers (Basel). 2021. PMID: 34439308 Free PMC article.
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study.
M'Baloula J, Tougeron D, Boilève A, Jeanbert E, Guimbaud R, Ben Abdelghani M, Durand A, Turpin A, Quesada S, Blanc JF, Artru P, Toullec C, Trouilloud I, Pellat A, Touchefeu Y, Pinot J, Caroli-Bosc FX, Taïeb J, Doat S, Bouché O, Védie AL, de Mestier L, Muller M. M'Baloula J, et al. Among authors: durand a. Eur J Cancer. 2024 Nov;212:115051. doi: 10.1016/j.ejca.2024.115051. Epub 2024 Oct 1. Eur J Cancer. 2024. PMID: 39366210 Free article.
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.
Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, de la Motte Rouge T, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M. Becker O, et al. Among authors: durand a. Int J Gynecol Cancer. 2024 Oct 31:ijgc-2024-005815. doi: 10.1136/ijgc-2024-005815. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39481880
681 results